151 related articles for article (PubMed ID: 32199764)
1. The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.
Marcellino BK; Verstovsek S; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):415-421. PubMed ID: 32199764
[TBL] [Abstract][Full Text] [Related]
2. Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.
Chifotides HT; Verstovsek S; Bose P
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444441
[TBL] [Abstract][Full Text] [Related]
3. New approaches to tackle cytopenic myelofibrosis.
Reynolds SB; Pettit K
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
[TBL] [Abstract][Full Text] [Related]
4. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
5. Biological drivers of clinical phenotype in myelofibrosis.
Mascarenhas J; Gleitz HFE; Chifotides HT; Harrison CN; Verstovsek S; Vannucchi AM; Rampal RK; Kiladjian JJ; Vainchenker W; Hoffman R; Schneider RK; List AF
Leukemia; 2023 Feb; 37(2):255-264. PubMed ID: 36434065
[TBL] [Abstract][Full Text] [Related]
6. State-of-the-Art Review on Myelofibrosis Therapies.
Wang F; Qiu T; Wang H; Yang Q
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapies for Myelofibrosis.
Pettit K; Odenike O
Curr Hematol Malig Rep; 2017 Dec; 12(6):611-624. PubMed ID: 29098608
[TBL] [Abstract][Full Text] [Related]
8. Managing patients with myelofibrosis and low platelet counts.
Al-Ali HK; Vannucchi AM
Ann Hematol; 2017 Apr; 96(4):537-548. PubMed ID: 27209535
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutics and targets in myelofibrosis.
Waksal JA; Harrison CN; Mascarenhas JO
Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713
[TBL] [Abstract][Full Text] [Related]
10. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
[TBL] [Abstract][Full Text] [Related]
11. Cytopenic myelofibrosis: prevalence, relevance, and treatment.
Vachhani P; Verstovsek S; Bose P
Expert Opin Pharmacother; 2023 Jun; 24(8):901-912. PubMed ID: 37070147
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
[TBL] [Abstract][Full Text] [Related]
13. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
14. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.
Mughal TI; Vaddi K; Sarlis NJ; Verstovsek S
Int J Gen Med; 2014; 7():89-101. PubMed ID: 24501543
[TBL] [Abstract][Full Text] [Related]
15. Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment.
Sastow D; Mascarenhas J; Tremblay D
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e507-e520. PubMed ID: 35221248
[TBL] [Abstract][Full Text] [Related]
16. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
17. Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562644
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Fedratinib in Myelofibrosis.
Waksal JA; Tremblay D; Mascarenhas J
Onco Targets Ther; 2021; 14():4509-4521. PubMed ID: 34456572
[TBL] [Abstract][Full Text] [Related]
19. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
[TBL] [Abstract][Full Text] [Related]
20. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
